2-氯-6-吡咯烷-1-基吡啶 | 117362-51-3

• 分子结构分类: 有机化合物 - 有机氮化合物
• 中文名称: 2-氯-6-吡咯烷-1-基吡啶
• 英文名称: 2-chloro-6-pyrrolidine-1-ylpyridine
• 英文别名: 2-chloro-6-pyrrolidin-1-ylpyridine；2-Chloro-6-(pyrrolidin-1-yl)pyridine
• CAS: 117362-51-3
• 化学式: C₉H₁₁ClN₂
• mdl: MFCD04625620
• 分子量: 182.653
• InChiKey: VBMNALSMDIURFG-UHFFFAOYSA-N

物化性质

• 熔点：
  68 °C
• 沸点：
  316.4±27.0 °C(Predicted)
• 密度：
  1.224±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.444
• 拓扑面积：
  16.1
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 危险等级：
  IRRITANT

反应信息

• 作为反应物：
  描述：

  2-氯-6-吡咯烷-1-基吡啶 在 吡啶 、 potassium carbonate 作用下， 以 乙腈 为溶剂， 反应 68.0h， 生成 (8S,10S,13S,14S,17R)-17-Hydroxy-10,13-dimethyl-17-{2-[4-(6-pyrrolidin-1-yl-pyridin-2-yl)-piperazin-1-yl]-acetyl}-1,2,6,7,8,10,12,13,14,15,16,17-dodecahydro-cyclopenta[a]phenanthren-3-one
  参考文献：
  名称：

  Novel 21-aminosteroids that inhibit iron-dependent lipid peroxidation and protect against central nervous system trauma

  摘要：

  A novel class of 21-aminosteroids has been developed. Compounds within this series are potent inhibitors of iron-dependent lipid peroxidation in rat brain homogenates with IC50's as low as 3 microM. Furthermore, selected members enhance early neurological recovery and survival in a mouse head injury model. Significant improvement in the 1 h post-head-injury neurological status (grip test score) by as much as 168.6% of the control has been observed. The most efficacious compound in this assay (30) showed an increase in the 1-week survival of 78.6% as compared to 27.3% for the vehicle-treated mice in the head-injury model. Based on its biological profile, 21-[4-(2,6-di-1-pyrrolidinyl-4-pyrimidinyl)-1-piperazinyl]-16 alpha- methylpregna-1,4,9(11)-triene-3,20-dione monomethanesulfonate (30) was selected for further evaluation and is currently entering phase I clinical trials for the treatment of head and spinal trauma.

  DOI：

  10.1021/jm00166a010
• 作为产物：
  描述：

  四氢吡咯 、 2,6-二氯吡啶 在 potassium phosphate 作用下， 以 1,4-二氧六环 为溶剂， 反应 4.0h， 以95%的产率得到2-氯-6-吡咯烷-1-基吡啶
  参考文献：
  名称：

  氨基膦基镍体系催化的Negishi交叉偶联反应：一种高产率合成联芳基的可靠且通用的反应方案

  摘要：

  在25°C的空气中，用溶于THF的1,1'，1''-（膦三基）三哌啶（≈2.05当量）处理NiCl 2的NMP溶液，形成高活性的催化体系，用于交叉偶联多种电子激活，未激活，停用和正交用二芳基锌试剂取代，杂环和功能化的芳基溴化物和芳基氯化物。在仅0.1 mol％催化剂（基于镍）的存在下，于60°C在2 h内即可获得非常高的转化率和产率，因此催化剂负载量远低于Negishi反应的镍催化形式的典型报道。各种可能含有三氟甲基，氟化物或其他官能团的芳基卤化物，例如乙缩醛，酮，醚，酯，内酯，酰胺，亚胺，苯胺，烯烃，吡啶，喹啉和嘧啶，已成功转化为相应的联芳基。在两个反应伙伴中都可以接受电子和空间变化。实验观察表明，分子（Ni I / Ni III）机制有效。

  DOI：

  10.1002/chem.201101037

文献信息

• [EN] BIARYL DERIVATIVES AS GPR120 AGONISTS<br/>[FR] DÉRIVÉS DE BIARYLE EN TANT QU'AGONISTES DE GPR120
  申请人：LG LIFE SCIENCES LTD

  公开号：WO2014209034A1

  公开（公告）日：2014-12-31

  The present invention relates to biaryl derivatives of Formula 1, a method for preparing the same, a pharmaceutical composition comprising the same and use thereof. The biaryl derivatives of Formula 1 according to the present invention promote GLP-1 formation in the gastrointestinal tract and improve insulin resistance in the liver or in muscle due to anti-inflammatory action in macrophages, lipocytes, etc., and can accordingly be effectively used for preventing or treating diabetes, complications of diabetes, obesity, non-alcoholic fatty liver, steatohepatitis, osteoporosis or inflammation.

  本发明涉及公式1的联苯衍生物，一种制备该联苯衍生物的方法，包含该联苯衍生物的药物组合物以及其用途。根据本发明的公式1的联苯衍生物促进胃肠道中GLP-1的形成，并由于巨噬细胞、脂肪细胞等中的抗炎作用改善肝脏或肌肉中的胰岛素抵抗，因此可有效用于预防或治疗糖尿病、糖尿病并发症、肥胖、非酒精性脂肪肝、脂肪性肝炎、骨质疏松症或炎症。
• BIARYL DERIVATIVES AS GPR120 AGONISTS
  申请人：LG LIFE SCIENCES LTD.

  公开号：US20160168096A1

  公开（公告）日：2016-06-16

  The present invention relates to biaryl derivatives of Formula 1, a method for preparing the same, a pharmaceutical composition comprising the same and use thereof. The biaryl derivatives of Formula 1 according to the present invention promote GLP-1 formation in the gastrointestinal tract and improve insulin resistance in the liver or in muscle due to anti-inflammatory action in macrophages, lipocytes, etc., and can accordingly be effectively used for preventing or treating diabetes, complications of diabetes, obesity, non-alcoholic fatty liver, steatohepatitis, osteoporosis or inflammation.

  本发明涉及公式1的联苯衍生物，以及制备它们的方法、包含它们的药物组合物和使用方法。根据本发明的公式1的联苯衍生物能够促进胃肠道中的GLP-1形成，并通过对巨噬细胞、脂肪细胞等的抗炎作用改善肝脏或肌肉中的胰岛素抵抗，因此可以有效地用于预防或治疗糖尿病、糖尿病并发症、肥胖症、非酒精性脂肪肝、脂肪性肝炎、骨质疏松或炎症。
• BIARYL DERIVATIVE AS GPR120 AGONIST
  申请人：LG Chem, Ltd.

  公开号：EP3239143A2

  公开（公告）日：2017-11-01

  The present invention relates to a biaryl derivative expressed by the chemical formula 1, a method for producing the biaryl derivative, a pharmaceutical composition comprising same, and use of same, the biaryl derivative expressed by the chemical formula 1, as a GPR120 agonist, promoting GLP-1 generation in the gastro-intestinal tract, reducing insulin resistance in the liver, muscles and the like from anti-inflammatory activity in the macrophage, pancreatic cells and the like, and allowing effective use in prevention or treatment of inflammation or metabolic diseases such as diabetes, complications from diabetes, obesity, non-alcoholic fatty liver disease, fatty liver disease, and osteoporosis.

  本发明涉及一种由化学式1表示的生物芳基衍生物、生产该生物芳基衍生物的方法、包含该生物芳基衍生物的药物组合物以及该生物芳基衍生物的用途，由化学式1表示的生物芳基衍生物作为GPR120激动剂，促进胃肠道中GLP-1的生成、从巨噬细胞、胰腺细胞等的抗炎活性中降低肝脏、肌肉等的胰岛素抵抗，并可有效用于预防或治疗炎症或代谢性疾病，如糖尿病、糖尿病并发症、肥胖症、非酒精性脂肪肝、脂肪肝和骨质疏松症。
• Biaryl derivatives as GPR120 agonists
  申请人：LG CHEM, LTD.

  公开号：US10221138B2

  公开（公告）日：2019-03-05

  The present invention relates to biaryl derivatives of Formula 1, a method for preparing the same, a pharmaceutical composition comprising the same and use thereof. The biaryl derivatives of Formula 1 according to the present invention promote GLP-1 formation in the gastrointestinal tract and improve insulin resistance in the liver or in muscle due to anti-inflammatory action in macrophages, lipocytes, etc., and can accordingly be effectively used for preventing or treating diabetes, complications of diabetes, obesity, non-alcoholic fatty liver, steatohepatitis, osteoporosis or inflammation.

  本发明涉及式 1 的双芳基衍生物、其制备方法、包含其的药物组合物及其用途。根据本发明的式 1 的双芳基衍生物可促进胃肠道中 GLP-1 的形成，并由于在巨噬细胞、脂肪细胞等中的抗炎作用而改善肝脏或肌肉中的胰岛素抵抗，因此可有效用于预防或治疗糖尿病、糖尿病并发症、肥胖症、非酒精性脂肪肝、脂肪性肝炎、骨质疏松症或炎症。
• Biaryl derivative as GPR120 agonist
  申请人：LG CHEM, LTD.

  公开号：US11261186B2

  公开（公告）日：2022-03-01

  Compounds having the chemical formula 1, a method for producing the compounds of chemical formula 1, a pharmaceutical composition comprising same, and use thereof as a GPR120 agonist for prevention or treatment of inflammation or metabolic diseases such as diabetes, complications from diabetes, obesity, non-alcoholic fatty liver disease, fatty liver disease, and osteoporosis.

  具有化学式1的化合物，制备所述化学式1化合物的方法，包含所述化合物的药物组合物，以及将其用作一种GPR120激动剂，用于预防或治疗炎症或代谢性疾病，如糖尿病、糖尿病并发症、肥胖症、非酒精性脂肪肝病、脂肪肝病和骨质疏松症。